Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease
JA Delmez, E Slatopolsky - American Journal of Kidney Diseases, 1992 - Elsevier
Control of phosphorus accumulation in chronic renal insufficiency is crucial to the prevention
of secondary hyperparathyroidism and metastatic calcification. In early renal failure, calcitriol …
of secondary hyperparathyroidism and metastatic calcification. In early renal failure, calcitriol …
Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis
E Slatopolsky, C Weerts, S Lopez-Hilker… - … England Journal of …, 1986 - Mass Medical Soc
Phosphate binders that contain aluminum are frequently prescribed to treat
hyperphosphatemia in patients with chronic renal failure, but an accumulation of aluminum …
hyperphosphatemia in patients with chronic renal failure, but an accumulation of aluminum …
Hyperphosphataemia in Renal Failures: Causes, Consequences and Current Management
F Albaaj, AJ Hutchison - Drugs, 2003 - Springer
Hyperphosphataemia is prevalent among chronic renal failure and dialysis patients. It is
known to stimulate parathyroid hormone and suppress vitamin D3 production, thereby …
known to stimulate parathyroid hormone and suppress vitamin D3 production, thereby …
Are we mismanaging calcium and phosphate metabolism in renal failure?
CH Hsu - American Journal of Kidney Diseases, 1997 - Elsevier
Secondary hyperparathyroidism and renal osteodystrophy are the consequences of
abnormal calcium, phosphate, and calcitriol metabolism ensuing from renal failure …
abnormal calcium, phosphate, and calcitriol metabolism ensuing from renal failure …
Use of calcium carbonate as a phosphate binder in dialysis patients.
G Hercz, JA Kraut, DA Andress, N Howard… - Mineral and …, 1986 - europepmc.org
Aluminum-containing phosphate (Al-binders) employed to control serum phosphorus in
patients with chronic renal failure can be associated with the development of aluminum …
patients with chronic renal failure can be associated with the development of aluminum …
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
WF Finn - Clinical nephrology, 2006 - search.ebscohost.com
Aims: No conventional phosphate binder is entirely satisfactory for the treatment of
hyperphosphatemia in patients with end-stage renal disease (ESRD). Consequently, there …
hyperphosphatemia in patients with end-stage renal disease (ESRD). Consequently, there …
The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study
K Schaefer, J Scheer, G Asmus… - Nephrology Dialysis …, 1991 - academic.oup.com
A comparative study of long-term haemodialysis patients investigated the effects of calcium
acetate and calcium carbonate on concentrations of serum phosphate, calcium, and …
acetate and calcium carbonate on concentrations of serum phosphate, calcium, and …
Control of hyperphosphatemia among patients with ESRD
JA Coladonato - Journal of the American Society of Nephrology, 2005 - journals.lww.com
Derangements of mineral metabolism occur during the early stages of chronic kidney
disease (CKD). Hyperphosphatemia develops in the majority of patients with ESRD and has …
disease (CKD). Hyperphosphatemia develops in the majority of patients with ESRD and has …
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management
GA Block, FK Port - American Journal of Kidney Diseases, 2000 - Elsevier
Hyperphosphatemia is a predictable consequence of chronic renal failure and is present in
most patients on dialysis. Traditionally, the risk associated with elevated serum phosphorus …
most patients on dialysis. Traditionally, the risk associated with elevated serum phosphorus …
Calcium acetate control of serum phosphorus in hemodialysis patients
M Emmett, MD Sirmon, WG Kirkpatrick… - American journal of …, 1991 - Elsevier
Calcium acetate has many characteristics of an ideal phosphorus binder. It is a readily
soluble salt that avidly binds phosphorus in vitro at pH 5 and above. One-dose/one-meal …
soluble salt that avidly binds phosphorus in vitro at pH 5 and above. One-dose/one-meal …
相关搜索
- hyperphosphatemia and hyperparathyroidism dialysis patients
- phosphate binder dialysis patients
- patients with esrd control of hyperphosphatemia
- renal failure phosphate metabolism
- lanthanum carbonate treatment of hyperphosphatemia
- standard therapy treatment of hyperphosphatemia
- safety and efficacy treatment of hyperphosphatemia